{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:16:56Z","timestamp":1791584216018,"version":"4.3.4"},"reference-count":152,"publisher":"European Respiratory Society (ERS)","issue":"174","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2024,10,3]]},"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:p>The advent of cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy, especially the triple therapy combining the drugs elexacaftor, tezacaftor, ivacaftor (ETI), has significantly changed the course of the disease in people with cystic fibrosis (pwCF). ETI, which is approved for the majority (80\u201390%) of pwCF, partially restores CFTR channel function, resulting in improved mucociliary clearance and, consequently, improved lung function, respiratory symptoms and pulmonary exacerbations. The bacterial burden of classical CF pathogens such as<jats:italic>Pseudomonas aeruginosa<\/jats:italic>and<jats:italic>Staphylococcus aureus<\/jats:italic>is reduced without reaching eradication in the majority of infected patients. Limited data is available on less common or emerging bacterial pathogens. ETI has a positive effect on the lung microbiome but does not fully restore it to a healthy state. Due to the significant reduction in sputum production under ETI, respiratory samples such as deep-throat swabs are commonly taken, despite their inadequate representation of lower respiratory tract pathogens. Currently, there are still unanswered questions related to this new therapy, such as the clinical impact of infection with cystic fibrosis (CF) pathogens, the value of molecular diagnostic tests, the durability of the effects on respiratory infection and the role of fungal and viral infections. This article reviews the changes in bacterial lung infections and the microbiome in CF to provide evidence for the use of antibiotics in the era of ETI.<\/jats:p>","DOI":"10.1183\/16000617.0068-2024","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T09:46:03Z","timestamp":1733305563000},"page":"240068","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":29,"title":["Changing profile of bacterial infection and microbiome in cystic fibrosis: when to use antibiotics in the era of CFTR-modulator therapy"],"prefix":"10.1183","volume":"33","author":[{"given":"Justyna","family":"Milczewska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zulfiya","family":"Syunyaeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"\u017babi\u0144ska-Jaro\u0144","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"Sands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9090-7869","authenticated-orcid":false,"given":"Stephanie","family":"Thee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2024,12,4]]},"reference":[{"key":"2024120401452993000_33.174.240068.1","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jcf.2016.11.002","article-title":"Environmental scan of cystic fibrosis research worldwide","volume":"16","author":"Kelly","year":"2017","journal-title":"J Cyst Fibros"},{"key":"2024120401452993000_33.174.240068.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60327-5"},{"key":"2024120401452993000_33.174.240068.3","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0154-2022"},{"key":"2024120401452993000_33.174.240068.4","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2024120401452993000_33.174.240068.5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/01.JAA.0000515540.36581.92","article-title":"Keep them breathing: cystic fibrosis pathophysiology, diagnosis, and treatment","volume":"30","author":"Brown","year":"2017","journal-title":"JAAPA"},{"key":"2024120401452993000_33.174.240068.6","doi-asserted-by":"publisher","DOI":"10.1126\/science.7543698"},{"key":"2024120401452993000_33.174.240068.7","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200403-381WS"},{"key":"2024120401452993000_33.174.240068.8","doi-asserted-by":"publisher","DOI":"10.3390\/cells10112844"},{"key":"2024120401452993000_33.174.240068.9","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-016-2391-y"},{"key":"2024120401452993000_33.174.240068.10","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2006-0082SF"},{"key":"2024120401452993000_33.174.240068.11","doi-asserted-by":"publisher","DOI":"10.1126\/science.1223012"},{"key":"2024120401452993000_33.174.240068.12","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-017-1193-9"},{"key":"2024120401452993000_33.174.240068.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2011.06.002"},{"key":"2024120401452993000_33.174.240068.14","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu944"},{"key":"2024120401452993000_33.174.240068.15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-19240-2"},{"key":"2024120401452993000_33.174.240068.16","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1055\/s-0039-1698464","article-title":"Microbiology of cystic fibrosis airway disease","volume":"40","author":"Blanchard","year":"2019","journal-title":"Semin Respir Crit Care Med"},{"key":"2024120401452993000_33.174.240068.17","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200304-505SO"},{"key":"2024120401452993000_33.174.240068.18","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.3390\/ijms23073513","article-title":"The effect of CFTR modulators on airway infection in cystic fibrosis","volume":"23","author":"Harvey","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2024120401452993000_33.174.240068.19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241512365"},{"key":"2024120401452993000_33.174.240068.20","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02437-2022"},{"key":"2024120401452993000_33.174.240068.21","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ccm.2022.06.007","article-title":"The impact of highly effective modulator therapy on cystic fibrosis microbiology and inflammation","volume":"43","author":"Caverly","year":"2022","journal-title":"Clin Chest Med"},{"issue":"Suppl. 3","key":"2024120401452993000_33.174.240068.22","first-page":"S18","article-title":"Improving outcomes of infections in cystic fibrosis in the era of CFTR modulator therapy","volume":"54","author":"Saiman","year":"2019","journal-title":"Pediatr Pulmonol"},{"key":"2024120401452993000_33.174.240068.23","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1055\/s-0042-1758732","article-title":"Microbial epidemiology of the cystic fibrosis airways: past, present, and future","volume":"44","author":"Thornton","year":"2023","journal-title":"Semin Respir Crit Care Med"},{"key":"2024120401452993000_33.174.240068.24","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1055\/s-0042-1758851","article-title":"CFTR modulators: current status and evolving knowledge","volume":"44","author":"Regard","year":"2023","journal-title":"Semin Respir Crit Care Med"},{"key":"2024120401452993000_33.174.240068.25","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1002\/ppul.26486","article-title":"Radiological and long-term clinical response to elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis with advanced lung disease","volume":"58","author":"Aalbers","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"2024120401452993000_33.174.240068.26","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3390\/cells11071243","article-title":"CFTR modulator therapies: potential impact on airway infections in cystic fibrosis","volume":"11","author":"Saluzzo","year":"2022","journal-title":"Cells"},{"key":"2024120401452993000_33.174.240068.27","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.3390\/ijms24055010","article-title":"Revisiting host\u2013pathogen interactions in cystic fibrosis lungs in the era of CFTR modulators","volume":"24","author":"Ribeiro","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2024120401452993000_33.174.240068.28","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00037-15"},{"key":"2024120401452993000_33.174.240068.29","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.3390\/pathogens10091177","article-title":"Staphylococcus aureus and cystic fibrosis\u2013a close relationship. What can we learn from sequencing studies?","volume":"10","author":"Rumpf","year":"2021","journal-title":"Pathogens"},{"key":"2024120401452993000_33.174.240068.30","first-page":"CD011581","article-title":"Treatment for chronic methicillin-sensitive Staphylococcus aureus pulmonary infection in people with cystic fibrosis","volume":"7","author":"Ahmed","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"2024120401452993000_33.174.240068.31","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ppul.10127","article-title":"Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis","volume":"34","author":"Emerson","year":"2002","journal-title":"Pediatric Pulmon"},{"key":"2024120401452993000_33.174.240068.32","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro2907"},{"key":"2024120401452993000_33.174.240068.33","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jcf.2017.04.001","article-title":"Pseudomonas aeruginosa eradication: finally moving the needle?","volume":"16","author":"Cogen","year":"2017","journal-title":"J Cyst Fibros"},{"key":"2024120401452993000_33.174.240068.34","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu385"},{"key":"2024120401452993000_33.174.240068.35","doi-asserted-by":"publisher","DOI":"10.4248\/IJOS11026"},{"key":"2024120401452993000_33.174.240068.36","doi-asserted-by":"publisher","DOI":"10.1016\/S1286-4579(00)01259-4"},{"key":"2024120401452993000_33.174.240068.37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2010.03237.x"},{"key":"2024120401452993000_33.174.240068.38","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201408-395OC"},{"key":"2024120401452993000_33.174.240068.39","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)91881-L"},{"key":"2024120401452993000_33.174.240068.40","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-011-1182-5"},{"key":"2024120401452993000_33.174.240068.41","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00051-2019"},{"key":"2024120401452993000_33.174.240068.42","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.000763"},{"key":"2024120401452993000_33.174.240068.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2012.12.006"},{"key":"2024120401452993000_33.174.240068.44","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s10096-023-04648-z","article-title":"Stenotrophomonas maltophilia in people with cystic fibrosis: a systematic review of prevalence, risk factors and management","volume":"42","author":"Terlizzi","year":"2023","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2024120401452993000_33.174.240068.45","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jcf.2019.08.006","article-title":"Changing epidemiology of the respiratory bacteriology of patients with cystic fibrosis\u2013data from the European Cystic Fibrosis Society patient registry","volume":"19","author":"Hatziagorou","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2024120401452993000_33.174.240068.46","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-023-08468-6"},{"key":"2024120401452993000_33.174.240068.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2016.03.002"},{"key":"2024120401452993000_33.174.240068.48","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1055\/s-0042-1759883","article-title":"Nontuberculous mycobacteria in cystic fibrosis in the era of cystic fibrosis transmembrane regulator modulators","volume":"44","author":"Burke","year":"2023","journal-title":"Semin Respir Crit Care Med"},{"key":"2024120401452993000_33.174.240068.49","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1120577109"},{"key":"2024120401452993000_33.174.240068.50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0116029"},{"key":"2024120401452993000_33.174.240068.51","doi-asserted-by":"publisher","DOI":"10.1038\/ismej.2015.198"},{"key":"2024120401452993000_33.174.240068.52","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00832-2017"},{"key":"2024120401452993000_33.174.240068.53","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2018-211510"},{"key":"2024120401452993000_33.174.240068.54","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3390\/genes11050536","article-title":"The microbiome in cystic fibrosis pulmonary disease","volume":"11","author":"Fran\u00e7oise","year":"2020","journal-title":"Genes (Basel)"},{"key":"2024120401452993000_33.174.240068.55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0016384"},{"key":"2024120401452993000_33.174.240068.56","doi-asserted-by":"publisher","DOI":"10.1038\/srep10241"},{"key":"2024120401452993000_33.174.240068.57","doi-asserted-by":"publisher","DOI":"10.1111\/j.1462-2920.2010.02173.x"},{"key":"2024120401452993000_33.174.240068.58","doi-asserted-by":"publisher","DOI":"10.1038\/ismej.2010.175"},{"key":"2024120401452993000_33.174.240068.59","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201311-383OC"},{"key":"2024120401452993000_33.174.240068.60","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00432-15"},{"key":"2024120401452993000_33.174.240068.61","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201104-0655OC"},{"key":"2024120401452993000_33.174.240068.62","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S2213-2600(16)30081-9","article-title":"The nasal microbiota in infants with cystic fibrosis in the first year of life: a prospective cohort study","volume":"4","author":"Mika","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2024120401452993000_33.174.240068.63","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02235-2016"},{"key":"2024120401452993000_33.174.240068.64","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00096-2015"},{"key":"2024120401452993000_33.174.240068.65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0124124"},{"key":"2024120401452993000_33.174.240068.66","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2018-000374"},{"key":"2024120401452993000_33.174.240068.67","doi-asserted-by":"publisher","DOI":"10.1186\/s40064-015-1207-0"},{"key":"2024120401452993000_33.174.240068.68","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0062917"},{"key":"2024120401452993000_33.174.240068.69","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0164510"},{"key":"2024120401452993000_33.174.240068.70","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jcf.2023.11.010","article-title":"Longitudinal changes in the cystic fibrosis airway microbiota with time and treatment","volume":"23","author":"Einarsson","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2024120401452993000_33.174.240068.71","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201609-1954OC"},{"key":"2024120401452993000_33.174.240068.72","doi-asserted-by":"crossref","first-page":"e0314821","DOI":"10.1128\/mbio.03148-21","article-title":"Combining ivacaftor and intensive antibiotics achieves limited clearance of cystic fibrosis infections","volume":"12","author":"Durfey","year":"2021","journal-title":"mBio"},{"key":"2024120401452993000_33.174.240068.73","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jcf.2019.07.008","article-title":"The impact of CFTR modulator therapies on CF airway microbiology","volume":"19","author":"Rogers","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2024120401452993000_33.174.240068.74","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/1945892418815615","article-title":"Ivacaftor, a cystic fibrosis transmembrane conductance regulator potentiator, enhances ciprofloxacin activity against Pseudomonas aeruginosa","volume":"33","author":"Cho","year":"2019","journal-title":"Am J Rhinol Allergy"},{"key":"2024120401452993000_33.174.240068.75","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2014.02.004"},{"key":"2024120401452993000_33.174.240068.76","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.04.014"},{"key":"2024120401452993000_33.174.240068.77","doi-asserted-by":"crossref","first-page":"548613","DOI":"10.3389\/fcimb.2021.548613","article-title":"Changes in the cystic fibrosis airway microbiome in response to CFTR modulator therapy","volume":"11","author":"Yi","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"2024120401452993000_33.174.240068.78","doi-asserted-by":"crossref","first-page":"e0408322","DOI":"10.1128\/spectrum.04083-22","article-title":"Mutual effects of single and combined CFTR modulators and bacterial infection in cystic fibrosis","volume":"11","author":"Cigana","year":"2023","journal-title":"Microbiol Spectr"},{"key":"2024120401452993000_33.174.240068.79","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201404-0703OC"},{"key":"2024120401452993000_33.174.240068.80","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2017-210394"},{"key":"2024120401452993000_33.174.240068.81","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jcf.2019.05.015","article-title":"Disease progression in patients with cystic fibrosis treated with ivacaftor: data from national US and UK registries","volume":"19","author":"Volkova","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2024120401452993000_33.174.240068.82","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.jcf.2021.03.008","article-title":"Real-world use of ivacaftor in Canada: a retrospective analysis using the Canadian cystic fibrosis registry","volume":"20","author":"Kawala","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2024120401452993000_33.174.240068.83","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2020.11.008"},{"key":"2024120401452993000_33.174.240068.84","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jcf.2017.08.002","article-title":"Antibiotic exposure and interpersonal variance mask the effect of ivacaftor on respiratory microbiota composition","volume":"17","author":"Peleg","year":"2018","journal-title":"J Cyst Fibros"},{"key":"2024120401452993000_33.174.240068.85","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1513\/AnnalsATS.201902-122OC","article-title":"Ivacaftor is associated with reduced lung infection by key cystic fibrosis pathogens. A cohort study using national registry data","volume":"16","author":"Frost","year":"2019","journal-title":"Ann Am Thorac Soc"},{"key":"2024120401452993000_33.174.240068.86","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.24341"},{"key":"2024120401452993000_33.174.240068.87","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.26362"},{"key":"2024120401452993000_33.174.240068.88","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2023.03.002"},{"key":"2024120401452993000_33.174.240068.89","doi-asserted-by":"publisher","DOI":"10.1172\/JCI167957"},{"key":"2024120401452993000_33.174.240068.90","doi-asserted-by":"crossref","first-page":"e15756","DOI":"10.1016\/j.heliyon.2023.e15756","article-title":"Elexacaftor\u2013tezacaftor\u2013ivacaftor treatment improves systemic infection parameters and Pseudomonas aeruginosa colonization rate in patients with cystic fibrosis a monocentric observational study","volume":"9","author":"Schnell","year":"2023","journal-title":"Heliyon"},{"key":"2024120401452993000_33.174.240068.91","doi-asserted-by":"crossref","first-page":"e0145422","DOI":"10.1128\/spectrum.01454-22","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor therapy on the cystic fibrosis airway microbial metagenome","volume":"10","author":"Pallenberg","year":"2022","journal-title":"Microbiol Spectr"},{"key":"2024120401452993000_33.174.240068.92","doi-asserted-by":"crossref","first-page":"606","DOI":"10.3390\/ph15050606","article-title":"Elexacaftor\u2013tezacaftor\u2013ivacaftor as a final frontier in the treatment of cystic fibrosis: definition of the clinical and microbiological implications in a case\u2013control study","volume":"15","author":"Migliorisi","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"2024120401452993000_33.174.240068.93","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ijid.2023.11.013","article-title":"Use of elexacaftor\/tezacaftor\/ivacaftor leads to changes in detection frequencies of Staphylococcus aureus and Pseudomonas aeruginosa dependent on age and lung function in people with cystic fibrosis","volume":"139","author":"Dittrich","year":"2024","journal-title":"Int J Infect Dis"},{"key":"2024120401452993000_33.174.240068.94","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.arbres.2023.05.017","article-title":"Experience with elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis and advanced disease","volume":"59","author":"Hern\u00e1ndez","year":"2023","journal-title":"Arch Bronconeumol"},{"key":"2024120401452993000_33.174.240068.95","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00724-2021"},{"key":"2024120401452993000_33.174.240068.96","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jcf.2023.05.003","article-title":"Eradication of nontuberculous mycobacteria in people with cystic fibrosis treated with elexacaftor\/tezacaftor\/ivacaftor: a multicenter cohort study","volume":"23","author":"Wiesel","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2024120401452993000_33.174.240068.97","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jcf.2023.03.021","article-title":"Eradication of Mycobacterium abscessus infection in cystic fibrosis with initiation of elexacaftor\/tezacaftor\/ivacaftor","volume":"23","author":"McParland","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2024120401452993000_33.174.240068.98","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro.2017.14"},{"key":"2024120401452993000_33.174.240068.99","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0451-9"},{"key":"2024120401452993000_33.174.240068.100","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00185-2021"},{"key":"2024120401452993000_33.174.240068.101","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1164\/rccm.201407-1381OC","article-title":"Regulatory T-cell impairment in cystic fibrosis patients with chronic Pseudomonas infection","volume":"191","author":"Hector","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2024120401452993000_33.174.240068.102","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201206-1150OC"},{"key":"2024120401452993000_33.174.240068.103","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02153-2022"},{"key":"2024120401452993000_33.174.240068.104","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s41030-021-00158-5","article-title":"Real-world long-term ivacaftor for cystic fibrosis in France: clinical effectiveness and healthcare resource utilization","volume":"7","author":"Hubert","year":"2021","journal-title":"Pulm Ther"},{"key":"2024120401452993000_33.174.240068.105","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jcf.2022.05.007","article-title":"VOCAL: An observational study of ivacaftor for people with cystic fibrosis and selected non-G551D-CFTR gating mutations","volume":"22","author":"Simmonds","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2024120401452993000_33.174.240068.106","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s41030-020-00115-8","article-title":"Real-world outcomes among patients with cystic fibrosis treated with ivacaftor: 2012\u20132016 experience","volume":"6","author":"Higgins","year":"2020","journal-title":"Pulm Ther"},{"key":"2024120401452993000_33.174.240068.107","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1513\/AnnalsATS.201802-149OC","article-title":"Longitudinal trends in real-world outcomes after initiation of ivacaftor. A cohort study from the Cystic Fibrosis Registry of Ireland","volume":"16","author":"Kirwan","year":"2019","journal-title":"Ann Am Thorac Soc"},{"key":"2024120401452993000_33.174.240068.108","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2014.09.005"},{"key":"2024120401452993000_33.174.240068.109","doi-asserted-by":"crossref","first-page":"107455","DOI":"10.1016\/j.rmed.2023.107455","article-title":"The impact of elexacaftor\/tezacaftor\/ivacaftor therapy on the pulmonary management of adults with cystic fibrosis: an expert-based Delphi consensus","volume":"220","author":"Gramegna","year":"2023","journal-title":"Respir Med"},{"key":"2024120401452993000_33.174.240068.110","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908639"},{"key":"2024120401452993000_33.174.240068.111","doi-asserted-by":"crossref","first-page":"100690","DOI":"10.1016\/j.lanepe.2023.100690","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF Registry","volume":"32","author":"Sutharsan","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"2024120401452993000_33.174.240068.112","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32597-8"},{"key":"2024120401452993000_33.174.240068.113","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac117"},{"key":"2024120401452993000_33.174.240068.114","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.03079-2020"},{"key":"2024120401452993000_33.174.240068.115","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jcf.2022.01.012","article-title":"Sustained effectiveness of elexacaftor\u2013tezacaftor\u2013ivacaftor in lung transplant candidates with cystic fibrosis","volume":"21","author":"Martin","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2024120401452993000_33.174.240068.116","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1055\/s-0042-1758731","article-title":"Advanced cystic fibrosis lung disease and lung transplantation in the era of cystic fibrosis transmembrane conductance regulator modulators","volume":"44","author":"O'Carroll","year":"2023","journal-title":"Semin Respir Crit Care Med"},{"key":"2024120401452993000_33.174.240068.117","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.jcf.2023.06.012","article-title":"Impact of lumacaftor\/ivacaftor and tezacaftor\/ivacaftor on treatment response in pulmonary exacerbations of F508del\/F508del cystic fibrosis","volume":"22","author":"McElvaney","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2024120401452993000_33.174.240068.118","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jcf.2023.11.012","article-title":"Inhaled antimicrobial prescribing for Pseudomonas aeruginosa infections in Europe","volume":"23","author":"Sloan","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2024120401452993000_33.174.240068.119","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1569-1993(22)00936-5","article-title":"Provider practices in the management of pulmonary exacerbations in the era of highly effective modulator therapy","volume":"21","author":"Toporek","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2024120401452993000_33.174.240068.120","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41522-020-00171-7","article-title":"The human respiratory tract microbial community structures in healthy and cystic fibrosis infants","volume":"6","author":"Pust","year":"2020","journal-title":"NPJ Biofilms Microbiomes"},{"key":"2024120401452993000_33.174.240068.121","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199409083311003"},{"key":"2024120401452993000_33.174.240068.122","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jcf.2024.02.011","article-title":"Remote endpoints for clinical trials in cystic fibrosis: report from the US CF foundation remote endpoints task force","volume":"23","author":"Hoppe","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2024120401452993000_33.174.240068.123","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200812-1845PP"},{"key":"2024120401452993000_33.174.240068.124","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2018.02.006"},{"key":"2024120401452993000_33.174.240068.125","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2022-219943"},{"key":"2024120401452993000_33.174.240068.126","doi-asserted-by":"crossref","first-page":"e0222323","DOI":"10.1371\/journal.pone.0222323","article-title":"Upper versus lower airway microbiome and metagenome in children with cystic fibrosis and their correlation with lung inflammation","volume":"14","author":"Kirst","year":"2019","journal-title":"PLoS One"},{"key":"2024120401452993000_33.174.240068.127","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jcf.2021.08.031","article-title":"Comparison of microbial composition of cough swabs and sputum for pathogen detection in patients with cystic fibrosis","volume":"21","author":"Fenn","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2024120401452993000_33.174.240068.128","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30171-1"},{"key":"2024120401452993000_33.174.240068.129","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2022.01.006"},{"key":"2024120401452993000_33.174.240068.130","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/S1569-1993(23)00259-X","article-title":"WS13.01 The Cystic Fibrosis Home Sputum-Induction Trial (CF-HomeSpIT - ISRCTN86523335) to evaluate home sputum-induction and early morning saliva sampling in children with cystic fibrosis","volume":"22","author":"Ronchetti","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2024120401452993000_33.174.240068.131","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jcf.2023.03.008","article-title":"Effects of postage on recovery of pathogens from cystic fibrosis sputum samples","volume":"22","author":"Hatfield","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2024120401452993000_33.174.240068.132","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-018-3612-9"},{"key":"2024120401452993000_33.174.240068.133","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jcf.2018.02.008","article-title":"Early detection using qPCR of Pseudomonas aeruginosa infection in children with cystic fibrosis undergoing eradication treatment","volume":"17","author":"Blanchard","year":"2018","journal-title":"J Cyst Fibros"},{"key":"2024120401452993000_33.174.240068.134","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2017.12.007"},{"key":"2024120401452993000_33.174.240068.135","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2016.11.016"},{"key":"2024120401452993000_33.174.240068.136","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201907-493OC"},{"key":"2024120401452993000_33.174.240068.137","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201503-0578OC"},{"key":"2024120401452993000_33.174.240068.138","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2020-215556"},{"key":"2024120401452993000_33.174.240068.139","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02029-2022"},{"key":"2024120401452993000_33.174.240068.140","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2007-3139"},{"key":"2024120401452993000_33.174.240068.141","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2013-204000"},{"key":"2024120401452993000_33.174.240068.142","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2013.06.004"},{"key":"2024120401452993000_33.174.240068.143","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1513\/AnnalsATS.202306-576OC","article-title":"Prevalence and clinical impact of respiratory viral infections from the STOP2 study of cystic fibrosis pulmonary exacerbations","volume":"21","author":"Thornton","year":"2023","journal-title":"Ann Am Thorac Soc"},{"key":"2024120401452993000_33.174.240068.144","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1055\/s-0042-1758728","article-title":"Respiratory viruses and cystic fibrosis","volume":"44","author":"Brackenborough","year":"2023","journal-title":"Semin Respir Crit Care Med"},{"key":"2024120401452993000_33.174.240068.145","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02182-16"},{"key":"2024120401452993000_33.174.240068.146","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jcf.2018.10.001","article-title":"Prevalence, geographic risk factor, and development of a standardized protocol for fungal isolation in cystic fibrosis: results from the international prospective study \u201cMFIP\u201d","volume":"18","author":"Delhaes","year":"2019","journal-title":"J Cyst Fibros"},{"key":"2024120401452993000_33.174.240068.147","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1164\/rccm.201908-1585OC","article-title":"Aspergillus infections and progression of structural lung disease in children with cystic fibrosis","volume":"201","author":"Breuer","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2024120401452993000_33.174.240068.148","doi-asserted-by":"publisher","DOI":"10.1111\/cea.12595"},{"key":"2024120401452993000_33.174.240068.149","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu944"},{"key":"2024120401452993000_33.174.240068.150","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.jcf.2022.09.007","article-title":"Advent of elexacaftor\/tezacaftor\/ivacaftor for cystic fibrosis treatment: what consequences on Aspergillus-related diseases? Preliminary insights","volume":"21","author":"Chesnay","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2024120401452993000_33.174.240068.151","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2023-002049"},{"key":"2024120401452993000_33.174.240068.152","unstructured":"Cystic Fibrosis Foundation . Patient Registry 2022 Annual Data Report. Date last updated: September 2023. Date last accessed: 20 September 2024. www.cff.org\/media\/31216\/download"}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/16000617.0068-2024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:08:10Z","timestamp":1740373690000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/16000617.0068-2024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":152,"journal-issue":{"issue":"174","published-online":{"date-parts":[[2024,12,4]]},"published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1183\/16000617.0068-2024"],"URL":"https:\/\/doi.org\/10.1183\/16000617.0068-2024","relation":{},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"value":"0905-9180","type":"print"},{"value":"1600-0617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10]]}}}